Literature DB >> 16697867

Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance.

James W F Catto1, Arndt Hartmann, Robert Stoehr, Emma Bolderson, Ishtiaq Rehman, Derek J Rosario, Freddie C Hamdy, Mark Meuth.   

Abstract

PURPOSE: UC is a disease of the entire urothelium, characterized by multiplicity and multifocality. The clonal relationship among multiple UCs has implications regarding adjuvant chemotherapy. It has been investigated in studies of chromosomal alteration and single gene mutation. However, these genetic changes can occur in unrelated tumors under similar carcinogenic selection pressures. Tumors with high MSI have numerous DNA mutations, of which many provide no selection benefit. While these tumors represent an ideal model for studying UC clonality, their low frequency has prevented their previous investigation.
MATERIALS AND METHODS: We investigated 32 upper and lower urinary tract UCs with high MSI and 4 nonUC primary cancers in 9 patients. We used the high frequency and specificity of individual DNA mutations in these tumors (MSI at 17 loci) and the early timing of epigenetic events (methylation of 7 gene promoters) to investigate tumor clonality.
RESULTS: Molecular alterations varied among tumors from different primary organs but they appeared related in the UCs of all 9 patients. While 7 patients had a high degree of concordance among UCs, in 2 the UCs shared only a few similar alterations. Genetic and epigenetic abnormalities were frequently found in normal urothelial samples.
CONCLUSIONS: Multiple UCs in each patient appeared to arise from a single clone. The molecular order of tumor development varied from the timing of clinical presentation and suggested that residual malignant cells persist in the urinary tract despite apparent curative surgery. These cells lead to subsequent tumor relapse and new methods are required to detect and eradicate them.

Entities:  

Mesh:

Year:  2006        PMID: 16697867     DOI: 10.1016/S0022-5347(06)00256-4

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  16 in total

1.  Prognostic value and efficacy valuation of postoperative intravesical instillation in primary urothelial carcinomas of upper urinary tract.

Authors:  Xiaheng Deng; Xiao Yang; Yidong Cheng; Xuzhong Liu; Bian Wu; Zijie Wang; Zhengkai Huang; Kang Liu; Ruizhe Zhao; Jun Wang; Qiang Lu; Chao Qin; Changjun Yin
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 2.  Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours.

Authors:  David R Yates; James W F Catto
Journal:  World J Urol       Date:  2012-09-18       Impact factor: 4.226

3.  Preoperative positive urine cytology is a risk factor for subsequent development of bladder cancer after nephroureterectomy in patients with upper urinary tract urothelial carcinoma.

Authors:  Yasuyuki Kobayashi; Takashi Saika; Yoshiyuki Miyaji; Michinao Saegusa; Ryoji Arata; Naoki Akebi; Tadasu Takenaka; Daisuke Manabe; Yasutomo Nasu; Hiromi Kumon
Journal:  World J Urol       Date:  2011-07-30       Impact factor: 4.226

4.  Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma.

Authors:  Marco Cosentino; Joan Palou; Josep M Gaya; Alberto Breda; Oscar Rodriguez-Faba; Humberto Villavicencio-Mavrich
Journal:  World J Urol       Date:  2012-05-03       Impact factor: 4.226

Review 5.  Endoscopic Treatment of Upper Tract Urothelial Carcinoma.

Authors:  Daniel P Verges; Costas D Lallas; Scott G Hubosky; Demetrius H Bagley
Journal:  Curr Urol Rep       Date:  2017-04       Impact factor: 3.092

Review 6.  Perioperative chemotherapy for upper tract urothelial cancer.

Authors:  Ajjai S Alva; Surena F Matin; Seth P Lerner; Arlene O Siefker-Radtke
Journal:  Nat Rev Urol       Date:  2012-04-10       Impact factor: 14.432

7.  The neutrophil-to-lymphocyte ratio as a predictor of intravesical recurrence in patients with upper urinary tract urothelial carcinoma treated with radical nephroureterectomy.

Authors:  Nozomu Kishimoto; Tetsuya Takao; Sohei Kuribayashi; Gaku Yamamichi; Kosuke Nakano; Masataka Kawamura; Koichi Tsutahara; Go Tanigawa; Seiji Yamaguchi
Journal:  Int J Clin Oncol       Date:  2016-09-10       Impact factor: 3.402

8.  Distinct microRNA alterations characterize high- and low-grade bladder cancer.

Authors:  James W F Catto; Saiful Miah; Helen C Owen; Helen Bryant; Katie Myers; Ewa Dudziec; Stéphane Larré; Marta Milo; Ishtiaq Rehman; Derek J Rosario; Erica Di Martino; Margaret A Knowles; Mark Meuth; Adrian L Harris; Freddie C Hamdy
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

9.  Dynamic Change in p63 Protein Expression during Implantation of Urothelial Cancer Clusters.

Authors:  Takahiro Yoshida; Hiroaki Okuyama; Masashi Nakayama; Hiroko Endo; Yasuhiko Tomita; Norio Nonomura; Kazuo Nishimura; Masahiro Inoue
Journal:  Neoplasia       Date:  2015-07       Impact factor: 5.715

10.  Bladder cancer: a simple model becomes complex.

Authors:  Giovanni Battista Di Pierro; Caterina Gulia; Cristiano Cristini; Giorgio Fraietta; Lorenzo Marini; Pietro Grande; Vincenzo Gentile; Roberto Piergentili
Journal:  Curr Genomics       Date:  2012-08       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.